Association between investigated SNPs and clinical outcome
| Parameter | Test variables | HR (95% CI) | P value |
| Univariate analysis (PFS) | |||
| IFNG c.874T>A | AA+AT vs TT | 0.76 (0.58 to 0.99) | 0.045 |
| IL2RA c.64+5006T>C | CC+CT vs TT | 0.80 (0.62 to 1.04) | 0.098 |
| WHO performance status | 0 vs ≥1 | 0.66 (0.46 to 0.95) | 0.027 |
| Sex | Male vs female | 1.38 (1.06 to 1.80) | 0.018 |
| Multivariate analysis (PFS) | |||
| IFNG c.874T>A | AA+AT vs TT | 0.79 (0.58 to 1.07) | 0.131 |
| WHO performance status | 0 vs ≥1 | 0.66 (0.45 to 0.95) | 0.024 |
| Sex | Male vs female | 1.26 (0.92 to 1.71) | 0.148 |
| | | | |
| IL2RA c.64+5006T>C | CC+CT vs TT | 0.81 (0.60 to 1.10) | 0.177 |
| WHO performance status | 0 vs ≥1 | 0.65 (0.45 to 0.93) | 0.019 |
| | | | |
| Sex | Male vs female | 1.29 (0.95 to 1.76) | 0.101 |
| IFNG c.874T>A | AA+AT vs TT | 0.76 (0.55 to 1.05) | 0.093 |
| WHO performance status | 0 vs ≥1 | 0.52 (0.34 to 0.77) | 0.001 |
| Sex | Male vs female | 1.45 (1.03 to 2.02) | 0.32 |
| Univariate analysis (OS) | |||
| IFNG c.874T>A | AA+AT vs TT | 0.72 (0.55 to 0.95) | 0.021 |
| WHO PS | 0 vs ≥1 | 0.52 (0.35 to 0.77) | 0.001 |
| Sex | Male vs female | 1.40 (1.05 to 1.86) | 0.023 |
| Multivariate analysis (OS) | |||
| IFNG c.874T>A | AA+AT vs TT | 0.76 (0.55 to 1.05) | 0.093 |
| WHO performance status | 0 vs ≥1 | 0.52 (0.34 to 0.77) | 0.001 |
| Sex | Male vs female | 1.45 (1.03 to 2.02) | 0.32 |
| Parameter | Test variables | OR (95% CI) | P value |
| Univariate analysis (BOR) | |||
| IL10 c.387+284C>A | AA vs AA +AC | 0.25 (0.07 to 0.89) | 0.033 |
| ZAP70 −21–4127C>A | AA vs CC+AC | 0.50 (0.25 to 0.98) | 0.045 |
| Primary tumor | Other vs adeno | 0.63 (0.40 to 0.98) | 0.041 |
| Multivariate analysis (BOR) | |||
| IL10 c.387+284C>A | AA vs AA +AC | 0.24 (0.07 to 0.84) | 0.026 |
| Primary tumor | Other vs adeno | 0.61 (0.39 to 0.96) | 0.031 |
| | | | |
| ZAP70 −21–4127C>A | AA vs CC+AC | 0.49 (0.24 to 0.97) | 0.042 |
| Primary tumor | Other vs adeno | 0.61 (0.39 to 0.96) | 0.033 |
Univariate and multivariate analysis of the association between germline SNPs (except those related to GZMB variation; those are shown in table 2) and PFS, OS, or BOR. Only SNPs that were associated with OS/PFS/BOR (p value <0.1) are shown and included in the multivariate analysis. Significance is marked by *.
BOR, best overall response; OS, overall survival; PFS, progression-free survival; SNPs, single-nucleotide polymorphisms; WHO PS, WHO performance status.